» Articles » PMID: 28900321

Pattern of Adverse Drug Reactions to Anticancer Drugs: A Quantitative and Qualitative Analysis

Overview
Publisher Thieme
Specialty Oncology
Date 2017 Sep 14
PMID 28900321
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Anticancer drugs contribute significantly to the global burden of adverse drug reactions (ADRs). Any attempt to quantify their magnitude and provide upgraded knowledge would help oncologists in writing safer prescriptions.

Aim: This observational follow-up study was conducted on newly diagnosed cancer patients receiving anticancer therapy with an aim to determine the frequency, severity, causality, predictability, and preventability of ADRs.

Subjects And Methods: The patients were followed up for 6 months for the appearance of adverse events. Data were analyzed using IBM SPSS Statistics for Windows, Version 22.0. (Armonk, NY) and presented in the form of descriptive statistics.

Results: Each patient was prescribed approximately 6.85 ± 1.51 (mean ± standard error) drugs on average. All the patients (100%) receiving anticancer chemotherapy had ADRs. Alopecia, nausea and vomiting, burning tingling, and numbness were the most frequently encountered ADRs. The incidence of alopecia ( < 0.0004), nausea ( < 0.03), and oral ulceration ( < 0.02) was higher in females. Maximum reactions were of Grade 2 (69.53%). Most of the reactions (75.80%) appeared within 10 days of receiving the first cycle. 99.58% reactions were not serious. According to the WHO - The Uppsala Monitoring Centre criteria, 99.47% ADRs fell in possible category. According to the Naranjo's algorithm, 100% ADRs fell in probable category. About 94.80% reactions were found to be predictable. About 56.47% reactions were probably preventable, and 43.53% reactions were not preventable.

Conclusion: Multiple ADRs were seen in newly diagnosed cancer patients. Most of them were predictable, of mild-to-moderate severity, nonserious, and preventable. A majority of the ADRs recovered over time.

Citing Articles

Prevalence of renal insufficiency and factors associated among selected cancer patients on chemotherapy at Ocean Road Cancer Institute in Tanzania: a cross-sectional study.

Rajabu H, Hinderaker S, Mnandi P, Mutagonda R BMC Cancer. 2024; 24(1):763.

PMID: 38918707 PMC: 11201107. DOI: 10.1186/s12885-024-12419-y.


Metal organic framework-based variable-size nanoparticles for tumor microenvironment-responsive drug delivery.

Wang Y, Gao N, Li X, Ling G, Zhang P Drug Deliv Transl Res. 2024; 14(7):1737-1755.

PMID: 38329709 DOI: 10.1007/s13346-023-01500-x.


Pharmacovigilance Study of Anticancer Drugs in a Tertiary Care Teaching Hospital in North India: A Retrospective Study.

Kumar Sr R, Jindal Sr A, Garg P, Kaur A, Kumar S, Raj R Cureus. 2023; 15(9):e44984.

PMID: 37822427 PMC: 10562879. DOI: 10.7759/cureus.44984.


Active Pharmacovigilance Study: A Follow-Up Model of Oral Anti-Cancer Drugs under Additional Monitoring.

Carvalho da Silva S, Jesus M, Roque F, Herdeiro M, Costa E Sousa R, Duarte A Curr Oncol. 2023; 30(4):4139-4152.

PMID: 37185428 PMC: 10137106. DOI: 10.3390/curroncol30040315.


Pattern of Adverse Drug Reactions Associated with the Use of Anticancer Drugs in an Oncology-Based Hospital of Nepal.

Tamang R, Bharati L, Khatiwada A, Ozaki A, Shrestha S JMA J. 2022; 5(4):416-426.

PMID: 36407064 PMC: 9646287. DOI: 10.31662/jmaj.2021-0015.


References
1.
Lau P, Stewart K, Dooley M . The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you?. Support Care Cancer. 2004; 12(9):626-33. DOI: 10.1007/s00520-004-0622-5. View

2.
Surendiran A, Balamurugan N, Gunaseelan K, Akhtar S, Reddy K, Adithan C . Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study. Indian J Pharmacol. 2010; 42(1):40-3. PMC: 2885639. DOI: 10.4103/0253-7613.62412. View

3.
Routledge P, OMahony M, Woodhouse K . Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 2004; 57(2):121-6. PMC: 1884428. DOI: 10.1046/j.1365-2125.2003.01875.x. View

4.
Tran D, Sinclair R, Schwarer A, Chow C . Permanent alopecia following chemotherapy and bone marrow transplantation. Australas J Dermatol. 2000; 41(2):106-8. DOI: 10.1046/j.1440-0960.2000.00405.x. View

5.
Trueb R . Chemotherapy-induced alopecia. Semin Cutan Med Surg. 2009; 28(1):11-4. DOI: 10.1016/j.sder.2008.12.001. View